{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:05:36Z","timestamp":1779894336885,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA119170"],"award-info":[{"award-number":["CA119170"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA160040"],"award-info":[{"award-number":["5T32CA160040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R01DE026941"],"award-info":[{"award-number":["R01DE026941"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"crossref","award":["GRA.VL19.C3"],"award-info":[{"award-number":["GRA.VL19.C3"]}],"id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00280-019-04018-7","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T18:02:26Z","timestamp":1578506546000},"page":"573-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors"],"prefix":"10.1007","volume":"85","author":[{"given":"William B.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula W.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Waud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Gilbert-Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Achyut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turang","family":"Behbahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Ealick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-3354","authenticated-orcid":false,"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"4018_CR1","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.2174\/1381612823666171109101851","volume":"23","author":"WB Parker","year":"2017","unstructured":"Parker WB, Sorscher EJ (2017) Use of E. coli purine nucleoside phosphorylase in the treatment of solid tumors. Curr Pharm Des 23:7003\u20137024","journal-title":"Curr Pharm Des"},{"key":"4018_CR2","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1158\/0008-5472.CAN-04-0012","volume":"64","author":"JS Hong","year":"2004","unstructured":"Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA III, Parker WB, Sorscher EJ (2004) Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 64:6610\u20136615","journal-title":"Cancer Res."},{"key":"4018_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.cgt.7700520","volume":"10","author":"WB Parker","year":"2003","unstructured":"Parker WB, Allan PW, Hassan AEA, Secrist JA III, Sorscher EJ, Waud WR (2003) Anti-tumor activity of 2-fluoro-2\u2019-deoxyadenosine against tumors that express E. coli purine nucleoside phosphorylase. Cancer Gene Ther 10:23\u201329","journal-title":"Cancer Gene Ther"},{"key":"4018_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.gt.3301698","volume":"9","author":"D Voeks","year":"2002","unstructured":"Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, Russell PJ (2002) Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 9:759\u2013768","journal-title":"Gene Ther"},{"key":"4018_CR5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/jgm.629","volume":"6","author":"R Martiniello-Wilks","year":"2004","unstructured":"Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, Russell PJ (2004) Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 6:1343\u20131357","journal-title":"J Gene Med."},{"key":"4018_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/jgm.701","volume":"7","author":"S Deharvengt","year":"2005","unstructured":"Deharvengt S, Wack S, Aprahamian M, Hajri A (2005) Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med. 7:672\u2013680","journal-title":"J Gene Med."},{"key":"4018_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.cgt.7701013","volume":"14","author":"E Kikuchi","year":"2007","unstructured":"Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N (2007) Bochner BH (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther. 14:279\u2013286","journal-title":"Cancer Gene Ther."},{"key":"4018_CR8","doi-asserted-by":"publisher","first-page":"10939","DOI":"10.1158\/0008-5472.CAN-07-1252","volume":"67","author":"G Ungerechts","year":"2007","unstructured":"Ungerechts G, Springfield C, Frenzke ME, Lampe J, Johnston P, Parker WB, Sorscher EJ, Cattaneo R (2007) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res. 67:10939\u201310947","journal-title":"Cancer Res."},{"key":"4018_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/cgt.2011.30","volume":"18","author":"S Bossow","year":"2011","unstructured":"Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G (2011) Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 18:598\u2013608","journal-title":"Cancer Gene Ther"},{"key":"4018_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/jgm.1620","volume":"13","author":"X Xie","year":"2011","unstructured":"Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X (2011) Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 13:680\u2013691","journal-title":"J Gene Med."},{"key":"4018_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0006-2952(98)00034-3","volume":"55","author":"WB Parker","year":"1998","unstructured":"Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, Bennett LL Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55:1673\u20131681","journal-title":"Biochem Pharmacol"},{"key":"4018_CR12","first-page":"3339","volume":"55","author":"BW Hughes","year":"1995","unstructured":"Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RI Jr, Parker WB, Sorscher EJ (1995) Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55:3339\u20133345","journal-title":"Cancer Res."},{"key":"4018_CR13","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1074\/jbc.273.4.2322","volume":"273","author":"BW Hughes","year":"1998","unstructured":"Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ (1998) Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J. Biol. Chem. 273:2322\u20132328","journal-title":"J. Biol. Chem."},{"key":"4018_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/cgt.2011.4","volume":"18","author":"WB Parker","year":"2011","unstructured":"Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ (2011) Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase. Cancer Gene Ther 18:390\u2013398","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"4018_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/annonc\/mdv196","volume":"26","author":"EL Rosenthal","year":"2015","unstructured":"Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hung FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ (2015) Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann Oncol 26(7):1481\u20131487","journal-title":"Ann Oncol"},{"key":"4018_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00280-012-1908-9","volume":"70","author":"EJ Sorscher","year":"2012","unstructured":"Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB (2012) In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol. 70:321\u2013329","journal-title":"Cancer Chemother Pharmacol."},{"key":"4018_CR17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/S0021-9258(18)50147-2","volume":"237","author":"RB Scott","year":"1962","unstructured":"Scott RB, Brown GB (1962) The action of xanthine oxidase on some 2-substituted adenines. J Biol Chem 237:3215\u20133216","journal-title":"J Biol Chem"},{"key":"4018_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1089\/hum.1997.8.14-1637","volume":"8","author":"WB Parker","year":"1997","unstructured":"Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 8:1637\u20131644","journal-title":"Hum Gene Ther"},{"key":"4018_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0091-679X(08)60603-2","volume":"43","author":"TC Becker","year":"1994","unstructured":"Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgard CB (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43:161\u2013189","journal-title":"Methods Cell Biol"},{"key":"4018_CR20","unstructured":"Wold WSM (1999) (eds) Adenovirus methods and protocols. Methods in molecular medicine, vol 21. Humana Press Totowa, New Jersey"},{"key":"4018_CR21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hed.25627","volume":"41","author":"TE Behbahani","year":"2019","unstructured":"Behbahani TE, Rosenthal EL, Parker WB, Sorscher EJ (2019) Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck. Head Neck 41:1979\u20131983","journal-title":"Head Neck"},{"key":"4018_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/hum.2005.16.339","volume":"16","author":"B Bharara","year":"2005","unstructured":"Bharara B, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA III, Parker WB, Waud WR (2005) Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus based glioma therapy. Hum Gene Ther 16:339\u2013347","journal-title":"Hum Gene Ther"},{"key":"4018_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/15257779908041562","volume":"18","author":"JA Secrist III","year":"1999","unstructured":"Secrist JA III, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, Sorscher EJ (1999) Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18:745\u2013757","journal-title":"Nucleosides Nucleotides"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-04018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-04018-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-04018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:21:27Z","timestamp":1609978887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-04018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-04018-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"3 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Parker and Dr. Sorscher have ownership interests in PNP Therapeutics and serve on the Board of Directors for the company, which develops products used in research described by the paper. Drs. Parker and Sorscher are also inventors of technology being evaluated in studies described by this report. The terms of this arrangement for Dr. Sorscher have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Paula Allan and Jeong Hong also have minor equity interest in this company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}